Navigation Links
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Date:5/29/2012

overall survival benefit," said Denise A. Yardley, MD, breast program leader, senior investigator at the Sarah Cannon Research Institute and principal investigator of the study. "Moreover, the addition of entinostat to exemestane translated into an increase in progression-free survival of over six months in the subset of patients treated with this novel combination that demonstrated protein lysine hyperacetylation.  This suggests that evaluating evidence of protein hyperacetylation may be an exciting opportunity to explore whether we could use this biomarker to identify patients most likely to benefit from the addition of entinostat to standard hormone therapy.  These results continue to support the promise of entinostat for women with advanced breast cancer and I am eager to move forward with the confirmatory phase 3 study."

ENCORE 301 (ENtinostat Combinations Overcoming REsistance) was a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 post-menopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer, progressing on treatment with the non-steroidal aromatase inhibitors anastrozole or letrozole.  The study hit the primary endpoint of progression-free survival and preliminary analysis indicated an overall survival benefit. Entinostat was well tolerated with fatigue, nausea and uncomplicated neutropenia as the most commonly occurring adverse events. Pharmacodynamic analysis in a subset of patients linked for the first time a readout of histone deacetylase inhibitor activity with clinical outcome.

The abstract titled, "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase 2 study of exemestane with and without entinostat in ER+ post-menopausal women with metastatic breast cancer" highlighted the following results:

  • Analysis of OS across m
    '/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
(Date:7/2/2015)... July 2, 2015   EVO Aesthetic Center and ... provider for non-invasive aesthetics in Lakeway, Texas ... treatments with the Astanza Duality laser. The medical spa ... through various medical and laser procedures. Their addition of ... a clear solution to their tattoo regret. ...
(Date:7/2/2015)... July 2, 2015 Pharma Major Lupin ... ZAO "Biocom" in Russia subject to ... Russian pharmaceutical market which recorded RUB 765 billion in sales, ... in the world in 2014 (IMS Health). For over a ... to continue with this trend, projecting Russia ...
Breaking Medicine Technology:Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3
... 21, 2011 Robbins Umeda LLP, a shareholder ... possible breaches of fiduciary duty and other violations of ... Pharmaceutical Company (NYSE: KV-A, KV-B). (Logo: ... focuses on whether officials at KV Pharmaceuticals breached their ...
... the vaccines division of Sanofi (EURONEXT: SAN and NYSE: ... a new study evaluating the immunogenicity and safety of ... 65 years of age and older. Currently licensed influenza ... circulate in a given year. The data were presented ...
Cached Medicine Technology:Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:7/2/2015)... ... 2015 , ... Five individuals from Loma Linda University Health ... disaster training. The team – composed of four clinicians and one administrative staff ... attended the training, which is dedicated to preparing first responders for a mass ...
(Date:7/2/2015)... ... ... Hand sanitizers have become extremely popular with an annual industry growth rate ... and radio host Sharon Kleyne, hand sanitizers can effectively decrease the presence of disease ... must be applied correctly and users must be aware of its limitations. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief operating officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/2/2015)... ... , ... Throughout the month of April, Casey’s General Stores invited customers to ... July 7, Casey’s General Stores Chairman and CEO, Bob Myers, will present a check ... national nonprofit dedicated to restoring a sense of self, restoring the family unit, and ...
(Date:7/2/2015)... Arlington, VA (PRWEB) , ... July 02, 2015 , ... ... the enabler of enterprise collaboration across platforms and devices, today announced it was ... SaaS for its Citizen Connect Platform. The award, given out by the Government Technology ...
Breaking Medicine News(10 mins):Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4
... slight elevation was linked to coronary artery calcification in study ... of phosphorus are associated with a higher risk of heart ... phosphorus levels and coronary artery calcification (CAC) in nearly 900 ... of heart disease risk factors. CAC is an early sign ...
... The Cornea and Laser Eye Institute is participating in a ... safely and effectively reduce the need for reading glasses. ... , The investigational AcuFocus Corneal Inlay (ACI) ... which is the loss of near vision, and reduce dependency ...
... FreedomVOICE® proposes ... and offers tips to business owners to develop a work at home policy. , ... Encinitas, CA (Vocus) -- FreedomVOICE®, creators of the ... of the H1N1 virus in the workplace., , ,Whether we like it or not, the H1N1 ...
... DIEGO, Nov. 5 Volcano Corporation (Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral artery ... quarter of fiscal 2009. , The results for the quarter ... over revenues of $44.1 million in the third quarter of ...
... aid understanding of human diseases, scientists say , THURSDAY, ... domestic horse has been sequenced, an accomplishment that will ... of human health, according to an international team of ... it easier to understand all genomes, including our own. ...
... A drug already approved for the treatment of lymphoma may ... in children and teens, according to an early-stage study published ... The study drug, Bortezomib, was found to be effective against ... While key experiments were in animals, the cancer studied closely ...
Cached Medicine News:Health News:Phosphorus Levels May Predict Heart Disease 2Health News:Near vision research study 2Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 2Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 3Health News:FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 4Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 2Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 3Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 4Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 5Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 6Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 7Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 8Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 9Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 10Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 11Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 12Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 13Health News:Volcano Reports 22 Percent Increase in Third Quarter Revenues 14Health News:Complete Horse Genome Sequence Revealed 2Health News:Approved lymphoma drug shows promise in early tests against bone cancer 2
... The COMPACT Portable II A/B ... images close to analog quality. ... simply nothing like it. Keep ... system or take it to ...
The ultimate ultrasound system for clinical ophthalmologists....
... Eye care in the ... and flexibility. The Alcon® UltraScan® ... multifunction system targeted at clinical ... Biometry. Easy-to-use software, permits step-by-step ...
... Micro-Incision Cataract Surgery (MICS) Is ... unique double-step hexagonal shape, the ... for MICS. The consistently sharp-edged ... allow you to obtain accurate ...
Medicine Products: